中等症から重症の喘息に対するENV-294:成人を対象とした12週間の研究
中等症から重症の喘息を有する成人参加者におけるENV-294の有効性、安全性、および薬物動態を評価するための第2相、無作為化、二重盲検、プラセボ対照、並行群間、12週間試験
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA).
Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Clinical Operations
- メール:env-294.clinicaltrials@enveda.com
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35209
- 募集
- Enveda Investigative Site
-
-
California
-
Los Angeles、California、アメリカ、90025
- 募集
- Enveda Investigative Site
-
San Jose、California、アメリカ、95117
- 募集
- Enveda Investigative Site
-
West Hills、California、アメリカ、91307
- 募集
- Enveda Investigative Site
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ、80907
- 募集
- Enveda Investigative Site
-
-
Florida
-
Hialeah、Florida、アメリカ、33012
- 募集
- Enveda Investigative Site
-
Miami、Florida、アメリカ、33135
- 募集
- Enveda Investigative Site
-
-
Georgia
-
Albany、Georgia、アメリカ、31707
- 募集
- Enveda Investigative Site
-
-
Illinois
-
Maryville、Illinois、アメリカ、62062
- 募集
- Enveda Investigative Site
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- 募集
- Enveda Investigative Site
-
-
Kentucky
-
Owensboro、Kentucky、アメリカ、42301
- 募集
- Enveda Investigative Site
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- 募集
- Enveda Investigative Site
-
-
Michigan
-
Southfield、Michigan、アメリカ、48075
- 募集
- Enveda Investigative Site
-
-
Missouri
-
St Louis、Missouri、アメリカ、63141
- 募集
- Enveda Investigative Site
-
-
New York
-
The Bronx、New York、アメリカ、10455
- 募集
- Enveda Investigative Site
-
-
Oregon
-
Clackamas、Oregon、アメリカ、97015
- 募集
- Enveda Investigative Site
-
Medford、Oregon、アメリカ、97504
- 募集
- Enveda Investigative Site
-
-
South Carolina
-
North Charleston、South Carolina、アメリカ、29406
- 募集
- Enveda Investigative Site
-
-
Texas
-
McKinney、Texas、アメリカ、75069
- 募集
- Enveda Investigative Site
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53792
- 募集
- Enveda Investigative Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Able to read, understand, and sign an informed consent form before any study procedures
- Male or female adults aged 18 to 75 years with a physician diagnosis of moderate to severe asthma for at least 12 months
- Receiving stable treatment with an inhaled corticosteroid (ICS) plus a long-acting beta₂-agonist (LABA) for at least 2 months before screening
- Pre-bronchodilator FEV₁ between 50% and 80% of predicted normal at screening and baseline
- Demonstrated bronchodilator reversibility
- ACQ-5 score ≥1.25 to ≤3.0 at screening and baseline
- History of at least one asthma exacerbation in the past 12 months requiring systemic corticosteroids or hospitalization/emergency care
Exclusion Criteria:
- Recent moderate or severe asthma exacerbation (within 4 weeks before screening)
- History of life-threatening asthma
- Other significant pulmonary disease
- Recent bronchial thermoplasty (within 2 years)
- Uncontrolled current or recurrent concomitant illness
- Recent use of biologic therapies for asthma (within 6 months or 5 half-lives)
- Require immunosuppressive medications or frequent systemic corticosteroids
- Current smokers or former smokers with significant smoking history
- Uncontrolled hypertension
- Significant hepatic impairment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:ENV-294 Treatment Arm
ENV-294 will be administered to those participants randomized to the treatment arm. |
ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks. |
|
プラセボコンパレーター:Placebo Arm
A placebo will be administered to those participants randomized to the placebo arm. |
Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence and Severity of Adverse Events
時間枠:From first dose through approximately 16 weeks
|
Number and percentage of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuation of study drug. |
From first dose through approximately 16 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Loss of Asthma Control Events
時間枠:Baseline to Week 12
|
Number and percentage of participants experiencing a loss of asthma control (LOAC) event during the treatment period, defined according to protocol-specified criteria |
Baseline to Week 12
|
|
Time to Loss of Asthma Control
時間枠:Baseline to Week 12
|
Time from the first dose of study drug to the first occurrence of a loss of asthma control (LOAC) event, as defined in the protocol. |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
時間枠:Baseline to Week 12
|
Change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV₁), measured using standardized spirometry. |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
時間枠:Baseline to Week 12
|
Change from Baseline in the Asthma Control Questionnaire (ACQ-5) |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
時間枠:Baseline to Week 12
|
Change from Baseline in the Asthma Quality of Life Questionnaire (AQLQ) |
Baseline to Week 12
|
|
Plasma concentration of ENV-294
時間枠:Baseline to Week 12
|
Plasma concentrations of ENV-294 will be measured at specified time points following oral administration of the investigational drug. |
Baseline to Week 12
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Gurpreet Ahluwalia, PhD、Enveda Therapeutics, Inc.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data (IPD) will not be shared. The data include sensitive health information that cannot be fully de-identified under current privacy standards, and the sponsor does not plan to make IPD available outside the study team. Summary results and aggregate data will be shared publicly as required by regulation.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。